Literature DB >> 22966327

Diagnostic value of carbohydrate antigens in supernatants and sediments of pleural effusions.

Daniela Terracciano1, Claudia Mazzarella, Marcellino Cicalese, Sonia Galzerano, Gianfranco Apostolico, Angelina DI Carlo, Angela Mariano, Ciriaco Cecere, Vincenzo Macchia.   

Abstract

A panel of tumour markers including carcinoembryonic antigen (CEA), carbohydrate antigen (Ca)15-3, Ca125 and Ca19-9 were measured in the lysate of sediments and in the supernatants of pleural effusions of patients with benign and malignant disease. The tumour markers were also measured in the serum of the same patients. Of these patients, 32 had benign diseases (12 trasudative effusions associated with cirrhosis and 20 with non-malignant exudates: 12 pleuritis and 8 other inflammations) and 103 had malignant effusions (37 breast cancers, 29 lung cancers, 10 ovary cancers, 6 kidney cancers, 11 mesotheliomas and 10 lymphomas). We showed the highest level of CEA in pleural effusions of lung cancer followed by that in pleural effusions of breast cancer; whereas Ca15-3 was very high in the pleural effusions of breast and lung cancer. Concerning the lysate of sediment, CEA was high in the pleural effusions of patients with lung cancer and Ca15-3 in those of patients with breast cancer. The other markers are much less useful. For the remaining tumours, none of the markers tested appear to aid in the diagnosis of disease. In conclusion, our data suggest that the combined determination of tumour markers on supernatants and sediments of pleural effusion may provide additional information on the nature of pleural effusion, especially for cases with negative cytology.

Entities:  

Year:  2010        PMID: 22966327      PMCID: PMC3436410          DOI: 10.3892/ol_00000082

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  19 in total

Review 1.  Diagnostic problems in serous effusions.

Authors:  C W Bedrossian
Journal:  Diagn Cytopathol       Date:  1998-08       Impact factor: 1.582

2.  New criteria for the differentiation between transudates and exudates.

Authors:  N S Paramothayan; J Barron
Journal:  J Clin Pathol       Date:  2002-01       Impact factor: 3.411

3.  Utility of tumour markers in the diagnosis of neoplastic pleural effusion.

Authors:  M E San Jose; D Alvarez; L Valdes; A Sarandeses; J M Valle; P Penela
Journal:  Clin Chim Acta       Date:  1997-09-30       Impact factor: 3.786

4.  Diagnostic value of tumor markers for differentiating malignant and benign pleural effusions of Iranian patients.

Authors:  Sied Mohammad Ali Ghayumi; Samrad Mehrabi; Mehrnossh Doroudchi; Abbas Ghaderi
Journal:  Pathol Oncol Res       Date:  2005-12-31       Impact factor: 3.201

5.  Comparative analysis of Light's criteria and other biochemical parameters for distinguishing transudates from exudates.

Authors:  I Gázquez; J M Porcel; M Vives; M C Vicente de Vera; M Rubio; M C Rivas
Journal:  Respir Med       Date:  1998-05       Impact factor: 3.415

6.  Diagnostic value of CYFRA 21-1, CEA, CA 19-9, CA 15-3, and CA 125 assays in pleural effusions: analysis of 116 cases and review of the literature.

Authors:  David Shitrit; Boris Zingerman; Ariella Bar-Gil Shitrit; Dekel Shlomi; Mordechai R Kramer
Journal:  Oncologist       Date:  2005-08

7.  New approaches in the diagnostic procedure of malignant pleural effusions.

Authors:  Daniela Terracciano; Angelina Di Carlo; Paolino Papa; Marcello Cicalese; Pierpaolo Maietta; Ciriaco Cecere; Angela Mariano; Vincenzo Macchia
Journal:  Oncol Rep       Date:  2004-07       Impact factor: 3.906

Review 8.  Diagnosis and management of malignant pleural effusions.

Authors:  K N Fenton; J D Richardson
Journal:  Am J Surg       Date:  1995-07       Impact factor: 2.565

9.  Diagnosis of pleural effusions. Experience with clinical studies, 1986 to 1990.

Authors:  M Marel; B Stastny; L Melínová; E Svandová; R W Light
Journal:  Chest       Date:  1995-06       Impact factor: 9.410

10.  Multilevel likelihood ratios for identifying exudative pleural effusions(*).

Authors:  John E Heffner; Steven A Sahn; Lee K Brown
Journal:  Chest       Date:  2002-06       Impact factor: 9.410

View more
  3 in total

1.  Management of occult malignant pleural disease firstly detected at thoracotomy for non-small cell lung cancer patients.

Authors:  Shaolei Li; Shanyuan Zhang; Miao Huang; Yuanyuan Ma; Yue Yang
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

2.  Clinical diagnostic utility of CA 15-3 for the diagnosis of malignant pleural effusion: A meta-analysis.

Authors:  Qiang Wu; Min Li; Shu Zhang; Lu Chen; Xingting Gu; Feng Xu
Journal:  Exp Ther Med       Date:  2014-10-30       Impact factor: 2.447

3.  Elevated tumor markers for monitoring tumor response to immunotherapy.

Authors:  Yi Yang; Xiaolin Jiang; Yun Liu; Huan Huang; Yanli Xiong; He Xiao; Kan Gong; Xuemei Li; Xunjie Kuang; Xueqin Yang
Journal:  EClinicalMedicine       Date:  2022-04-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.